External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home 2024 GI Cancers Symposium
Roche and Genentech at

2024 GI Cancers Symposium

January 18 - January 20
San Francisco, USA
conferences.asco.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
07:45 PM
Duration 90mins San Francisco, USA
MORPHEUS-EC: a phase Ib/II open-label, randomized study of tiragolumab plus atezolizumab plus chemotherapy in patients with previously untreated locally advanced unresectable or metastatic esophageal cancer
Dr Jong-Mu Sun
Oncology | Esophageal Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
09:15 PM
Duration 10mins Level 3, Ballroom, Moscone Center, San Francisco
SKYSCRAPER-08: a phase III, randomized, double-blind, placebo-controlled study of first-line tiragolumab + atezolizumab and chemotherapy in patients with esophageal squamous cell carcinoma (ESCC)
Dr Chih-Hung Hsu
Oncology | Esophageal Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
06:30 PM
Duration 10mins Level 3, Ballroom, Moscone Center, San Francisco
Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Results From a Randomized Proof-of-Concept Phase II Trial (IMbrave151)
Anthony B. El-Khoueiry, Zhenggang Ren, Hong Jae Chon, Joon Oh Park, Jin Won Kim, Tiziana Pressiani, Daneng Li, Lyudmila Zhukova, Andrew X. Zhu, Ming-Huang Chen, Stephen P. Hack, Stephanie Wu, Bo Liu, Xiangnan Guan, Shan Lu, Yulei Wang, Teresa Macarulla
Oncology | Biliary Tract Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
08:30 PM
Duration 90mins San Francisco, USA
Atezolizumab plus bevacizumab (A+B) in patients with unresectable hepatocellular carcinoma (uHCC): Real-world experience from a US community oncology network
Cosgrove, David; Tan, Amie; Osterland, Andrew; Hernandez, Sairy; Ogale, Sarika; Mahrus, Sami; Murphy, John; Wilson, Thomas; Patton, Gregory; Loaiza-Bonilla, Arturo; Singal, Amit
Oncology | Hepatocellular Carcinoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 90mins San Francisco, USA
Racial/ethnic disparities in the effectiveness of atezolizumab plus bevacizumab (A+B) vs. tyrosine kinase inhibitors (TKIs) among veterans with unresectable hepatocellular carcinoma (uHCC)
Kaplan, David E; Tan, Amie; Xiang, Cheryl; Mu, Fan; Hernandez, Sairy; Ogale, Sarika; Sundar, Manasvi; Lin, Yilu; Shi, Lizheng; Singal, Amit G.
Oncology | Hepatocellular Carcinoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 90mins San Francisco, USA
Comparing first-line (1L) atezolizumab plus bevacizumab (A+B) to lenvatinib (L) or sorafenib (S) in patients with unresectable hepatocellular carcinoma (uHCC): Findings from the National Veteran Health Administration (VHA) database
Kaplan, David E; Tan, Amie; Xiang, Cheryl; Mu, Fan; Hernandez, Sairy; Ogale, Sarika; Sundar, Manasvi; Lin, Yilu; Shi, Lizheng; Singal, Amit G.
Oncology | Hepatocellular Carcinoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.